Vanguard Group’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-11,856,648
| Closed | -$622M | – | 4267 |
|
|
2020
Q3 | $622M | Sell |
11,856,648
-798,308
| -6% | -$33M | 0.02% | 690 |
|
|
2020
Q2 | $421M | Buy |
12,654,956
+412,626
| +3% | +$13.1M | 0.01% | 835 |
|
|
2020
Q1 | $333M | Buy |
12,242,330
+322,542
| +3% | +$8.98M | 0.01% | 856 |
|
|
2019
Q4 | $235M | Buy |
11,919,788
+1,370,739
| +13% | +$21.9M | 0.01% | 1298 |
|
|
2019
Q3 | $137M | Buy |
10,549,049
+112,897
| +1% | +$1.36M | 0.01% | 1555 |
|
|
2019
Q2 | $130M | Buy |
10,436,152
+129,762
| +1% | +$1.72M | ﹤0.01% | 1609 |
|
|
2019
Q1 | $150M | Buy |
10,306,390
+592,414
| +6% | +$7.57M | 0.01% | 1521 |
|
|
2018
Q4 | $107M | Buy |
9,713,976
+2,116,026
| +28% | +$29.4M | ﹤0.01% | 1642 |
|
|
2018
Q3 | $200M | Buy |
7,597,950
+280,177
| +4% | +$7.57M | 0.01% | 1386 |
|
|
2018
Q2 | $150M | Buy |
7,317,773
+353,940
| +5% | +$7.6M | 0.01% | 1536 |
|
|
2018
Q1 | $126M | Buy |
6,963,833
+131,839
| +2% | +$2.2M | 0.01% | 1582 |
|
|
2017
Q4 | $95.3M | Buy |
6,831,994
+244,943
| +4% | +$3.31M | ﹤0.01% | 1749 |
|
|
2017
Q3 | $122M | Buy |
6,587,051
+343,284
| +5% | +$5.74M | 0.01% | 1601 |
|
|
2017
Q2 | $106M | Buy |
6,243,767
+290,090
| +5% | +$4.42M | 0.01% | 1643 |
|
|
2017
Q1 | $79.5M | Buy |
5,953,677
+195,996
| +3% | +$3.07M | ﹤0.01% | 1777 |
|
|
2016
Q4 | $86.7M | Buy |
5,757,681
+599,990
| +12% | +$7.92M | ﹤0.01% | 1715 |
|
|
2016
Q3 | $60.3M | Buy |
5,157,691
+406,875
| +9% | +$4.78M | ﹤0.01% | 1847 |
|
|
2016
Q2 | $51.3M | Sell |
4,750,816
-215,900
| -4% | -$2.23M | ﹤0.01% | 1898 |
|
|
2016
Q1 | $45.9M | Buy |
4,966,716
+126,410
| +3% | +$1.36M | ﹤0.01% | 1900 |
|
|
2015
Q4 | $71.8M | Buy |
4,840,306
+132,257
| +3% | +$2.21M | ﹤0.01% | 1695 |
|
|
2015
Q3 | $77.3M | Buy |
4,708,049
+370,661
| +9% | +$7.59M | 0.01% | 1617 |
|
|
2015
Q2 | $98.9M | Buy |
4,337,388
+1,011,587
| +30% | +$20.1M | 0.01% | 1533 |
|
|
2015
Q1 | $50.6M | Buy |
3,325,801
+264,806
| +9% | +$3.44M | ﹤0.01% | 1904 |
|
|
2014
Q4 | $36.9M | Sell |
3,060,995
-88,013
| -3% | -$1.01M | ﹤0.01% | 1987 |
|
|
2014
Q3 | $35.7M | Buy |
3,149,008
+34,991
| +1% | +$399K | ﹤0.01% | 1965 |
|
|
2014
Q2 | $37.6M | Sell |
3,114,017
-92,518
| -3% | -$1.09M | ﹤0.01% | 1967 |
|
|
2014
Q1 | $37.4M | Buy |
3,206,535
+153,529
| +5% | +$2.6M | ﹤0.01% | 1949 |
|
|
2013
Q4 | $54M | Buy |
3,053,006
+115,859
| +4% | +$1.95M | ﹤0.01% | 1740 |
|
|
2013
Q3 | $42.3M | Buy |
2,937,147
+161,543
| +6% | +$2.47M | ﹤0.01% | 1816 |
|
|
2013
Q2 | $41.8M | Buy |
+2,775,604
| New | +$36.6M | ﹤0.01% | 1751 |
|
Vanguard Group's MNTA Position: Q4 2020 in Review
Vanguard Group sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 11,856,648 shares — an estimated $622M sold.
Vanguard Group first reported a position in MNTA in Q2 2013 and held it in 30 quarters. The position peaked at $622M in Q3 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- Vanguard Group reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- Vanguard Group sold 11,856,648 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $622M.
- Vanguard Group first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 30 quarters.
- Vanguard Group's Momenta Pharmaceuticals, Inc. position peaked at $622M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on Vanguard Group's 13F filing for Q4 2020, filed 12 Feb 2021.